How should pancytopenia be evaluated in a 75-year-old male?

Pancytopenia Evaluation in a 75-Year-Old Male

In a 75-year-old male with pancytopenia, immediately obtain peripheral blood smear with differential, bone marrow aspiration and biopsy with cytogenetics, and comprehensive metabolic panel to distinguish between myelodysplastic syndrome (the most likely diagnosis in this age group), aplastic anemia, and other causes—as MDS represents the predominant etiology in elderly patients and requires specific risk stratification to guide treatment. 1

Initial Diagnostic Workup

The evaluation must proceed systematically to identify life-threatening causes while avoiding unnecessary delays:

Essential Laboratory Studies

• Complete blood count with differential and reticulocyte count - Document the severity of cytopenias and assess for dysplastic features 2

• Peripheral blood smear - Look specifically for:

  • Dysplastic neutrophils (hypolobulated nuclei, pseudo-Pelger-Huët anomaly)
  • Circulating blasts (even 1% is significant)
  • Macro-ovalocytes suggesting megaloblastic process
  • Hairy cells or abnormal lymphocytes 1

• Bone marrow aspiration AND trephine biopsy - This is mandatory, not optional 1. The biopsy provides:

  • Cellularity assessment (hypercellular in MDS vs hypocellular in aplastic anemia)
  • Blast percentage for WHO classification
  • Dysplasia quantification (≥10% in one or more lineages)
  • Ring sideroblasts with Prussian blue stain
  • Fibrosis assessment with reticulin stain
  • Immunohistochemistry for CD34+ cells

• Cytogenetic analysis - Conventional karyotyping is essential as specific abnormalities define prognosis and treatment 1, 2:

  • Del(5q), del(7q), trisomy 8, complex karyotype
  • These findings may be diagnostic even with <10% dysplasia 3

Secondary Evaluation

• Vitamin B12 and folate levels - Megaloblastic anemia is a reversible cause 4, 5, 6
• Serum erythropoietin level - Guides treatment decisions in lower-risk MDS 2
• HIV testing, hepatitis panel - Infectious causes 4
• Flow cytometry on blood and marrow:
  • PNH clone screening (CD55/CD59 deficiency) 2
  • Aberrant myeloid markers suggesting MDS
  • Lymphoproliferative disorders
  • Note: Flow cytometry blast counts should NOT replace morphologic assessment for prognostication 2

Medication and Exposure History

Document all medications, particularly:

• Chemotherapy agents (alkylating agents, purine analogs) 1
• Thionamides (methimazole can cause fatal pancytopenia even at low doses) 7
• Benzene or occupational exposures 1
• Alcohol consumption

Age-Specific Considerations for This 75-Year-Old

MDS is the most probable diagnosis given the patient's age—median age at MDS diagnosis is ~70 years, with incidence reaching 40-50 per 100,000 in patients ≥70 years 1. The WHO classification specifically notes that pancytopenia should be classified as MDS-Unclassified (MDS-U) when present 1, 3.

Critical Diagnostic Criteria for MDS

The diagnosis requires 2:

• Stable cytopenia for ≥6 months (or 2 months if specific karyotype or bilineage dysplasia present)
• Plus at least ONE of:
  • Dysplasia ≥10% in ≥1 major bone marrow lineage
  • Blast count 5-19%
  • MDS-associated karyotype (del(5q), del(20q), +8, -7/del(7q))

Risk Stratification Using IPSS-R

Once MDS is confirmed, calculate the Revised International Prognostic Scoring System (IPSS-R) score 8:

• Cytogenetic risk (very good to very poor)
• Bone marrow blast percentage
• Hemoglobin, platelet count, absolute neutrophil count

This determines whether the patient has:

• Lower-risk MDS (IPSS low/intermediate-1): Focus on quality of life, transfusion support, erythropoiesis-stimulating agents
• Higher-risk MDS (IPSS intermediate-2/high): Consider hypomethylating agents (azacitidine), allogeneic stem cell transplant if fit 1

Alternative Diagnoses to Exclude

Aplastic Anemia

• Hypocellular bone marrow (<25% cellularity)
• Absence of dysplasia or clonal cytogenetic abnormalities
• Consider HLA-DR15 testing and PNH clone if suspected 2, 9
• Critical: Without treatment, severe aplastic anemia has 70% mortality within 2 years 9

Hypersplenism

• Clinical splenomegaly on examination
• Relatively preserved bone marrow cellularity
• Most common cause in some series (29.2%) 5

Infections

• Disseminated histoplasmosis (consider Histoplasma antigen assay) 10
• HIV, hepatitis, tuberculosis
• May trigger hemophagocytic lymphohistiocytosis 10

Megaloblastic Anemia

• Macro-ovalocytes, hypersegmented neutrophils on smear
• Elevated MCV
• Low B12 (<200 pg/mL) or folate
• Common cause (13-74% in various series) 5, 6

Common Pitfalls to Avoid

1. Do not rely on flow cytometry blast percentage for prognosis—morphologic assessment by experienced hematopathologist is mandatory 2

2. Do not diagnose MDS without bone marrow examination—peripheral findings alone are insufficient 1

3. Do not assume drug-induced if on medications—still requires marrow evaluation to exclude primary marrow disorder 4

4. Do not delay bone marrow biopsy for nutritional replacement—can perform both simultaneously as B12/folate deficiency may coexist with MDS 4, 5

5. Recognize that "idiopathic cytopenia of undetermined significance" (ICUS) describes patients lacking sufficient morphologic/cytogenetic evidence for definitive MDS diagnosis—these require close monitoring 3

When to Refer to Hematology

Immediate referral is warranted when:

• Pancytopenia confirmed on repeat CBC
• Circulating blasts present
• Severe cytopenias (ANC <500, platelets <20,000, Hb <7 g/dL)
• Bone marrow shows dysplasia, increased blasts, or abnormal cytogenetics
• Suspicion of acute leukemia or aggressive lymphoproliferative disorder

The hematologist will coordinate bone marrow examination if not already performed and determine need for advanced testing including next-generation sequencing for clonal mutations (TP53, SF3B1, etc.) that increasingly guide prognosis and therapy 8, 4.